Diabetes Mellitus, Type 2  >>  AZD1656  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD1656 / AstraZeneca
NCT00817778: Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Completed
2a
27
US
AZD1656, Placebo
AstraZeneca
Type 2 Diabetes
07/09
07/09
NCT00856908: Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

Completed
2a
20
US
AZD1656, Placebo
AstraZeneca
Type II Diabetes
08/09
08/09
NCT01020123 / 2009-012612-41: Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients

Completed
2
530
Europe, RoW
AZD1656, Placebo, Glipizide
AstraZeneca
Type II Diabetes Mellitus
02/11
02/11
NCT01152385: Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Completed
2
224
Japan
AZD1656, Placebo
AstraZeneca
Type 2 Diabetes Mellitus
05/11
05/11

Download Options